公开(公告)号：AT264303T

公开(公告)日：2004-04-15

申请号：AT98963249

申请日：1998-12-16

Applicant: ABBOTT LAB

Inventor： CARROLL WILLIAM A ,  HOLLADAY MARK W ,  SULLIVAN JAMES P ,  DRIZIN IRENE ,  ZHANG HENRY Q

IPC: A61K31/4365 ,  A61K31/47 ,  A61K31/4743 ,  A61P1/00 ,  A61P1/14 ,  A61P9/08 ,  A61P9/12 ,  A61P11/06 ,  A61P13/02 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/08 ,  C07C45/29 ,  C07D215/36 ,  C07D221/04 ,  C07D495/04 ,  C07D495/14 ,  C07D211/84 ,  A61K31/44 ,  A61K31/38

Abstract: Compounds having the formula are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.

公开(公告)号：CY2260B1

公开(公告)日：2003-07-04

申请号：CY0200010

申请日：2002-02-12

Applicant: ABBOTT LAB

Inventor： MEYER MICHAEL D ,  BASHA FATIMA ,  DRIZIN IRENE ,  WENDT MICHAEL D ,  ZHANG WEIJIANG ,  ALTENBACH ROBERT J ,  CARROLL WILLIAM A ,  KERWIN JAMES F ,  HAIGHT ANTHONY R

IPC: A61K31/517 ,  A61K31/519 ,  A61P13/08 ,  A61P13/10 ,  A61P15/04 ,  A61P43/00 ,  C07D207/26 ,  C07D311/58 ,  C07D491/04 ,  C07D491/052 ,  C07D495/04 ,  C07D519/00 ,  A61K31/415

Abstract: The present invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are alpha -1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are alpha -1 antagonist compositions and a method for antagonizing alpha -1 adrenoreceptors and treating BPH.

公开(公告)号：AR028987A1

公开(公告)日：2003-06-04

申请号：ARP000100931

申请日：2000-03-02

Applicant: ABBOTT LAB

Inventor： CARROLL WILLIAM A ,  KERWIN JAMES F ,  CHEN YIYUAN ,  MOORE JIMMIE L ,  DRIZIN IRENE

IPC: A61K31/435 ,  A61P9/12 ,  A61P11/06 ,  A61P13/00 ,  A61P15/10 ,  A61P25/08 ,  A61P25/28 ,  C07C45/29 ,  C07D221/04 ,  C07D221/06 ,  C07D401/04 ,  C07D405/04 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D211/82 ,  C07D215/20 ,  C07D211/90 ,  A61K31/473

Abstract: Compuestos derivados de ciclopentapiridin-cetona de formula (1), cuyos sustituyentes A, Ra y Rl están definidos en la memoria descriptiva. Dichos compuestos son utiles para tratar enfermedades que pueden prevenirse o mejorarse con abridores de canales de potasio. También se describen composiciones farmacéuticas que comprenden dichos compuestos asi como el uso de los mismos en la fabricacion de un medicamento util para tratar este tipo de enfermedades.

公开(公告)号：TR200101140T2

公开(公告)日：2002-07-22

申请号：TR200101140

申请日：1999-10-28

Applicant: ABBOTT LAB

Inventor： CARROLL WILLIAM A ,  AGRIOS KONSTANTINOS A ,  ALTENBACH ROBERT J ,  DRIZIN IRENE ,  KORT MICHAEL E

IPC: C07D335/02 ,  A61K20060101 ,  A61K31/436 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/55 ,  A61P20060101 ,  A61P1/00 ,  A61P9/12 ,  A61P11/06 ,  A61P13/00 ,  A61P15/00 ,  A61P15/02 ,  A61P15/10 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/08 ,  A61P25/28 ,  C07C45/00 ,  C07C45/29 ,  C07C45/41 ,  C07C45/63 ,  C07C205/44 ,  C07D20060101 ,  C07D211/86 ,  C07D219/00 ,  C07D309/30 ,  C07D471/04 ,  C07D471/14 ,  C07D491/00 ,  C07D491/04 ,  C07D491/052 ,  C07D491/14 ,  C07D491/147 ,  C07D491/153 ,  C07D495/04 ,  C07D495/14 ,  C07D513/00 ,  A61P13/10

Abstract: The present invention provides novel compounds of formula I which may be useful in hyperpolarizing cell membranes, opening potassium channels, relaxing smooth muscle cells, and inhibiting bladder contractions.

公开(公告)号：CO5150208A1

公开(公告)日：2002-04-29

申请号：CO00014719

申请日：2000-03-01

Applicant: ABBOTT LAB

Inventor： CARROLL WILLIAM A ,  YIYUAN CHEN ,  DRIZIN IRENE ,  KERWIN JAMES F ,  MOORE JIMMIE L

IPC: A61K31/12 ,  A61K31/435 ,  A61K31/44 ,  A61P9/12 ,  A61P11/06 ,  A61P13/00 ,  A61P15/10 ,  A61P25/08 ,  A61P25/28 ,  C07C45/29 ,  C07D221/04 ,  C07D221/06 ,  C07D401/04 ,  C07D405/04 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04

Abstract: Un compuesto que tiene la fórmula I o una sal, ester o amida del mismo farmacéuticamente aceptable, en donde la línea punteada representa la presencia de un enlace doble opcional; R1 es seleccionado del grupo que consiste de arilo y heteroarilo; A es seleccionado del grupo que consiste de hidrógeno, alquil, ciano, haloalquil, heteroaril, nitro y -C(O)R2, en donde R2 es seleccionado del grupo que consiste de alquil, haloalquil e hidroxi; R3 es seleccionado del grupo que consiste de hidrógeno, alquil y haloalquil; y A y R3 tomado juntos con el anillo al cual están unidos pueden formar un anillo carbocíclico de 5 o 6 miembros, dicho anillo carbocíclico de 5 o 6 miembros puede contener 1 o 2 enlaces dobles y puede ser substituido con 1 o 2 substituyentes seleccionados del grupo que consiste de hidrógeno, alquenil, alcoxi, alcoxialcoxi, alcoxialquil, alquil, alquinil, arilalcoxi, haloalquenil, haloalquil, halógeno, hidroxi, hidroxialquenil, hidroxialquil, oxo, y -NR4R5 en donde R4 y R5 son seleccionados independientemente del grupo que consiste de hidrógeno y alquilo C1-C4.

公开(公告)号：NZ504371A

公开(公告)日：2002-02-01

申请号：NZ50437198

申请日：1998-12-16

Applicant: ABBOTT LAB

Inventor： CARROLL WILLIAM A ,  HOLLADAY MARK W ,  SULLIVAN JAMES P ,  DRIZIN IRENE ,  ZHANG HENRY Q

IPC: A61K31/4365 ,  A61K31/47 ,  A61K31/4743 ,  A61P1/00 ,  A61P1/14 ,  A61P9/08 ,  A61P9/12 ,  A61P11/06 ,  A61P13/02 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/08 ,  C07C45/29 ,  C07D215/36 ,  C07D221/04 ,  C07D495/04 ,  C07D495/14 ,  C07D211/84 ,  A61K31/4709 ,  A61K31/38 ,  A61K31/4738

Abstract: A pyridine derivative or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof has the formula I wherein: R1 is alkyl; R2 is optionally substituted aryl or heteroaryl; n is 0-2; A is hydrogen, alkyl or -X-R3; R3 is alkyl or haloalkyl; X is -C(O)- or -S(O)p-; p is 1 or 2; R4 and R5 are independently hydrogen, alkyl or haloalkyl or R1 and R5 together with the ring to which they are attached form a 5-, 6- or 7-membered sulfur-containing ring with 1-2 double bonds and 0-2 oxo substituents; or A and R4 together with the ring to which they are attached form a 5-, 6-, or 7-membered carbocyclic ring with 1-2 double bonds and 0-1 oxo substituents or a 5-, 6- or 7-membered sulfur-containing ring with 1-2 double bonds and 0-2 oxo substituents, provided that one of R1 and R5 or A and R4 forms a ring. A cyclopenta[b]thiopyrano[2,3-e]pyridine derivative or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof has the formula II wherein R2 is optionally substituted aryl or heteroaryl; n is 1 or 2; X is -CH2-, -C(O)-, -S(O)-, or -S(O)2- and n' and n" are independently 1 to 3. A pharmaceutical composition thereof is useful for treating asthma, epilepsy, hypertension, Raynaud's syndrome, impotence, migraine, pain, eating disorders, urinary incontinence, functional bowel disorders, neurodegeneration or stroke.

公开(公告)号：HU0102895A2

公开(公告)日：2001-12-28

申请号：HU0102895

申请日：2000-03-06

Applicant: ABBOTT LAB

Inventor： CARROLL WILLIAM A ,  CHEN YIYUAN ,  DRIZIN IRENE ,  KERWIN JAMES F ,  MOORE JIMMIE L

IPC: A61K31/435 ,  A61P9/12 ,  A61P11/06 ,  A61P13/00 ,  A61P15/10 ,  A61P25/08 ,  A61P25/28 ,  C07C45/29 ,  C07D221/04 ,  C07D221/06 ,  C07D401/04 ,  C07D405/04 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D211/82

Abstract: Compounds of formula Iare useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.

公开(公告)号：PT805812E

公开(公告)日：2001-11-30

申请号：PT96903364

申请日：1996-01-11

Applicant: ABBOTT LAB

Inventor： BASHA FATIMA Z ,  MEYER MICHELLE D ,  ALTENBACH ROBERT J ,  CARROLL WILLIAM A ,  DRIZIN IRENE ,  KERWIN JAMES F ,  LEBOLD SUZANNE A ,  LEE EDMUND L ,  SIPPY KEVIN B ,  TIETJE KARIN R ,  YAMAMOTO DIANE M ,  PRATT JOHN K

IPC: A61K31/505 ,  A61K31/519 ,  A61P13/02 ,  A61P15/00 ,  A61P25/02 ,  C07D401/06 ,  C07D403/06 ,  C07D471/04 ,  C07D473/04 ,  C07D475/02 ,  C07D487/04 ,  C07D491/04 ,  C07D491/056 ,  C07D495/04 ,  C07D498/04 ,  C07D487/02 ,  C07D495/02 ,  C07D487/00

Abstract: The present invention relates to a compound of the formula and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are alpha -1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are alpha -1 antagonist compositions and a method for antagonizing alpha -1 receptors and treating BPH.

公开(公告)号：AT207071T

公开(公告)日：2001-11-15

申请号：AT97951555

申请日：1997-12-04

Applicant: ABBOTT LAB

Inventor： MEYER MICHAEL D ,  ALTENBACH ROBERT J ,  BASHA FATIMA ,  CARROLL WILLIAM A ,  DRIZIN IRENE ,  KERWIN JAMES F ,  WENDT MICHAEL D ,  HAIGHT ANTHONY R ,  ZHANG WEIJIANG

IPC: A61K31/517 ,  A61K31/519 ,  A61P13/08 ,  A61P13/10 ,  A61P15/04 ,  A61P43/00 ,  C07D207/26 ,  C07D311/58 ,  C07D491/04 ,  C07D491/052 ,  C07D495/04 ,  C07D519/00 ,  A61K31/415 ,  C07D311/00 ,  C07D209/00 ,  C07D221/00

Abstract: The present invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are alpha -1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are alpha -1 antagonist compositions and a method for antagonizing alpha -1 adrenoreceptors and treating BPH.

公开(公告)号：CA2407838A1

公开(公告)日：2001-11-08

申请号：CA2407838

申请日：2001-05-03

Applicant: ABBOTT LAB

Inventor： CARROLL WILLIAM A ,  KORT MICHAEL J ,  ALTENBACH ROBERT J ,  DRIZIN IRENE ,  AGRIOS KONSTANTINOS A

IPC: C07D335/02 ,  A61K20060101 ,  A61K31/436 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/4741 ,  A61K31/4743 ,  A61K31/55 ,  A61P20060101 ,  A61P1/00 ,  A61P9/12 ,  A61P11/06 ,  A61P13/00 ,  A61P13/10 ,  A61P15/00 ,  A61P15/02 ,  A61P15/10 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/08 ,  A61P25/28 ,  A61P29/02 ,  C07C45/00 ,  C07C45/29 ,  C07C45/41 ,  C07C45/63 ,  C07C205/44 ,  C07D20060101 ,  C07D211/86 ,  C07D219/00 ,  C07D309/30 ,  C07D309/32 ,  C07D471/04 ,  C07D471/14 ,  C07D491/00 ,  C07D491/04 ,  C07D491/052 ,  C07D491/14 ,  C07D491/147 ,  C07D491/153 ,  C07D495/04 ,  C07D495/14 ,  C07D513/00 ,  A61K31/4745

Abstract: The present invention provides novel compounds of formula (I), which may be useful in hyperpolarizing cell membranes, opening potassium channels, relaxi ng smooth muscle cells, and inhibiting bladder contractions.